

HIV DRUG RESISTANCE

LABORATORY-BASED SURVEY OF ACQUIRED HIV DRUG RESISTANCE USING REMNANT VIRAL LOAD SPECIMENS

APRIL 2021



LABORATORY-BASED SURVEY OF ACQUIRED HIV DRUG RESISTANCE USING REMNANT VIRAL LOAD SPECIMENS

APRIL 2021

Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens

ISBN 978-92-4-002541-7 (electronic version)

ISBN 978-92-4-002542-4 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgements	v
Abbreviations and acronyms	vi
Definitions	vii
Executive summary	viii
1. Introduction	1
1.1 Advantages of the survey method	1
1.2 Potential challenges related to the feasibility of the survey method	2
1.3 Overview	2
2. Survey planning: framework for assessing country readiness to implement surveys of acquired HIV drug resistance leveraging remnant viral load specimens	3
2.1 First step: assess the mandatory criteria	3
2.2 Second step: assess laboratory- and country-level data availability	5
2.3 Third step: assess viral load testing coverage and patient-level data completeness	6
2.4 Determining readiness to implement acquired HIV drug resistance surveys leveraging remnant viral load specimens	7
3. Survey methods	9
3.1 Overview	9
3.2 Survey outcomes	10
3.3 Eligibility criteria for remnant specimens	10
3.4 Interpreting the survey results	11
3.5 Survey sample size	11
3.6 Sampling procedures	13
3.7 Observed sample size	13
3.8 Data analysis	14
4. Implementation considerations	15
4.1 Convention for assigning survey identification numbers	15
4.2 Data extraction	15
4.3 Reporting data	15
4.4 Implementation overview: practical guide	16
5. Alternative approach for countries with viral load coverage $\geq 60\%$ but availability of required survey variables $< 80\%$	17
5.1 Overview	17
5.2 Viral load laboratory- and country-level data needed to implement this survey	17
5.3 First design phase: determining the required sample sizes and number of clinics to sample	18
5.4 Interventions and specimen collection for sampled clinics	20
5.5 Second design phase: allocating sample sizes across sampled clinics	20
5.6 Sampling procedures	21
5.7 Analysis	21

References	22
Annex 1. Checklist to assess country readiness to implement acquired HIV drug resistance surveys leveraging remnant viral load specimens	23
Annex 2. Modelled impact of missing data on acquired HIV drug resistance prevalence estimates	26
Annex 3. Statistical methods	28
A3.1 Calculating standard sample sizes	29
A3.3 Allocating samples across DTG and non-DTG strata	29
A3.4 Size inflation for genotyping failure	30
A3.5 Allocating samples across all viral load testing laboratories in a country	30
A3.6 Example: sample size calculations and allocation across strata using the formulas detailed in Annex 4	30
A3.7 Sampling procedures and observed sample size	32
A3.8 Analysis	33
A3.9 Stata code for the standard method described in Section 3	38
Annex 4. Example: sample size calculations and allocation across strata using the methods described in Section 3	44
Annex 5. Sample size calculations and allocation across strata among children and adolescents: special considerations	47
A5.1 The number of children and adolescents receiving DTG-containing regimens is few	47
A5.2 Budget considerations preclude assessing survey outcome by DTG and non-DTG-containing regimens among children and adolescents	48
Annex 6. Statistical methods for alternative survey activity described in Section 5	50
A6.1 Determining the required sample sizes, overall and by DTG and non-DTG eligible case specimens	52
A6.2 Inflating sample size for design effect and genotyping failure	53
A6.3 Determining the number of clinics to sample	54
A6.4 Allocating the number of clinics to sample across laboratories	55
A6.5 Interventions and specimen collection for sampled clinics	55
A6.6 Example: sample size calculations and allocation across strata using the formulas detailed in this annex	56
A6.7 Analysis	59
A6.8 Stata code for the alternative method described in Section 5	65
Annex 7. Example: sample size calculations and allocation across strata using the methods described in Section 5	72
A7.1 Example: the first design phase to determining the required sample sizes and number of clinics to sample	72
A7.2 Example: the second design phase to allocate the sample size of eligible case specimens to each sampled clinic	75
Annex 8. Budget considerations	77

ACKNOWLEDGEMENTS

Silvia Bertagnolio (WHO Department of Global HIV, Hepatitis and STI Programmes) conceived and coordinated the development of this document, in collaboration with Michael R. Jordan (Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA and the Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University, Boston, MA, USA). WHO acknowledges the technical inputs on Bethany Hedt-Gauthier and Stephanie Wu (Harvard University, Cambridge, MA, USA) who developed the statistical methods. WHO acknowledges the technical inputs of Amalia Giron and Seth Inzaule (Consultants, WHO Department of Global HIV, Hepatitis and STI Programmes). WHO thanks the United States Centers for Diseases Control and Prevention (Elliot Raizes, Juliana Da Silva, Amitabh Suthar, and Sherry Pals) and Fatim Cham (WHO-AFRO) and Giovanni Ravasi (PAHO) for the technical inputs to the initial draft of the document and the WHO HIVResNet Technical Working Group on Surveillance and Monitoring (Andrew Phillips, Natalie Dean, Derval Igoe, Steve Reynolds, Mathieu Maheu-Giroux, Urvi Parikh, Gillian Hunt, Emiliano Bisso, David Dunn, Chris Archibald, Charles Holmes, Philippe Glaziou, Santiago Avila, and Mohammad Chakroun) for their contribution. WHO thanks Rudo A. P. Kuwengwa (National ART programme, Eswatini) and Christine Watera (Uganda Virus Research Institute, Uganda), for critical input with respect to implementation considerations and thanks Mathieu Maheu-Giroux (McGill University, Montreal, Canada) for the mathematical modeling that informed the method section.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23997

